Diabetes Mellitus Type 1
Conditions
Brief summary
Increasing evidence suggests pancreatic islet beta-cell regeneration occurs throughout the course of the disease in patients with type 1 diabetes. Therefore, decreased beta-cell mass in type 1 diabetes may be improved through inhibition of beta-cell destruction and stimulation of proliferation, even after prolonged duration of disease. Physical activity improves insulin secretion via unknown underlying mechanisms. We recently observed that Interleukin-6 induces glucagon like Peptide (GLP)-1 production and release from the islet alpha-cell and the intestinal L-cell. Furthermore, exercise induces release of Interleukin-6 from skeletal muscle resulting in elevated circulating Interleukin-6 levels. Therefore we hypothesize that exercise-induced Interleukin-6 promotes glucagon like peptide-1 secretion from the islet α-cell and the intestinal L-cell, thereby providing a mechanism how physical activity can help maintain and improve beta-cell function in patients with type 1 diabetes. This mechanism can be enhanced by concomitant dipeptidyl peptidase-IV inhibition. Physical activity is also known to enhance insulin sensitivity and to attenuate the immune system activity. Therefore by combining physical activity and dipeptidyl peptidase-IV inhibition we aim to allow for beta-cell regeneration in a interventional randomized open-label study.
Interventions
DRUGSitagliptin
DRUGExercise
Sponsors
University Hospital, Basel, Switzerland
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
1. Type 1 diabetes (American Diabetes Association criteria) of \> 2 year duration that is judged to be stable by the investigator 2. No clinically significant change in treatment regimen for type 1 diabetes (defined as a 20% change) during the 3 months prior to Screening 3. Positive glutamic acid decarboxylase 65 and/or Islet Antigen (IA)-2 auto-antibodies 4. Age ≥ 18 years and ≤ 55 years 5. HbA1c \< 7.5% for the previous two measurements including the measurement taken at Screening (both measurements must occur within 6 months prior to enrollment) 6. Body-mass index (BMI) \> 18 and \< 28 kg/m2 7. Willingness to maintain current doses/regimens of vitamins and dietary supplements through the end of the study 8. For subjects with reproductive potential, a willingness to use contraceptive measures adequate to prevent the subject or the subject's partner from becoming pregnant during the study. Adequate contraceptive measures include hormonal methods used for two or more cycles prior to Screening (e.g., oral contraceptive pills, contraceptive patch, or contraceptive vaginal ring), double barrier methods (e.g., contraceptive sponge, diaphragm used in conjunction with contraceptive foam or jelly, and condom used in conjunction with contraceptive foam or jelly), intrauterine methods (IUD), sterilization (e.g., tubal ligation or a monogamous relationship with a vasectomized partner), and abstinence.
Exclusion criteria
1. Regular training of more than 90 minutes / week 2. History or signs of cardiovascular disease, proliferative retinopathy, nephropathy or neuropathy 3. Signs of current infection 4. Neutropenia 5. Anemia 6. Clinically significant kidney or liver disease 7. Current immunosuppressive treatment or documented immunodeficiency
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in beta-cell function as derived from change in C-peptide and glucose levels during the mixed meal test | Day 90 compared to baseline (Day 1 pre-dose) |
Secondary
| Measure | Time frame |
|---|---|
| Change in insulin requirements: 3-day average daily insulin dose | baseline (Day -3 through Day -1) compared to Day 90 (Day 87 through Day 89) |
| Change in HbA1c levels | baseline (Day 1 pre-dose) at Day 90 |
| Change in fasting glucose | baseline (Day 1 pre-dose) at Day 90 |
| Change in fasting glucagon and cortisol | baseline (Day 1 pre-dose) at Day 90 |
| Change in total number of hypoglycemic events compared to treatment groups | baseline (Day 1 pre-dose) to Day 90 |
| Change in markers of systemic inflammation | from baseline (Day 1 pre-dose) at Day 90 |
| Change in composition of immune cells | from baseline at Day 90 |
| Change in insulin sensitivity as derived from change in C-peptide and glucose levels during the mixed meal test | Day 90 compared to baseline (Day 1 pre-dose) |
| Change in lipids profile | baseline at Day 90 |
| Change in fatigue according to the Fatigue Scale for Motor and Cognitive Functions questionnaire | from baseline at Day 90 |
| Change in plasma copeptin and procalcitonin levels | from baseline (Day 1 pre-dose) at Day 90 |
| Change in retinal vascular diameter | Day 90 compared to baseline (Day 1 pre-dose) |
| Change in arterial stiffness | Day 90 compared to baseline (Day 1 pre-dose) |
| Change in fractalkine | Day 90 compared to baseline (Day 1 pre-dose) |
| Change in meal-stimulated GLP-1 and gastric inhibitory peptide | Day 90 compared to baseline |
Countries
Switzerland
Outcome results
None listed